⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2024Open Access

Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

Beatriz German Sarah Abou Alaiwi Kun-Lin Ho Jagpreet S. Nanda Marcos A. Fonseca Deborah L. Burkhart Anjali V. Sheahan Hannah E. Bergom Katherine L. Morel Himisha Beltran Justin H. Hwang Matthew L. Freedman Kate Lawrenson Leigh Ellis

View Full Paper

Ask AI

Bookmark

Share

Abstract

DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

German et al. (2024) studied this question.

synapsesocial.com/papers/68e59a30b6db64358753545f https://doi.org/10.1158/2767-9764.26898193

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer2024
2Supplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer2024
3Figure 3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer2024
4Figure 5 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer2024
5Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer2024